The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Allogene Therapeutics, Inc. Common Stock 019770106 46,213 1,798,163 SH   SOLE   1,798,163 0 0
Centessa Pharmaceuticals plc Ordinary Shares 152309100 65,661 3,931,818 SH   SOLE   3,931,818 0 0
Dyne Therapeutics, Inc. Common Stock 26818M108 48,071 2,960,046 SH   SOLE   2,960,046 0 0
Homology Medicines, Inc. Common Stock 438083107 6,067 770,845 SH   SOLE   770,845 0 0
Kinnate Biopharma, Inc. Common Stock 49705R105 63,246 2,747,433 SH   SOLE   2,747,433 0 0
Kronos Bio, Inc. Common Stock 50107A104 57,961 2,765,314 SH   SOLE   2,765,314 0 0
Oyster Point Pharma, Inc. Common Stock 69242L106 7,585 640,070 SH   SOLE   640,070 0 0
Praxis Precision Medicines, Inc. Common Stock 74006W108 54,348 2,939,329 SH   SOLE   2,939,329 0 0